Arcturus Therapeutics (NASDAQ:ARCT) Raised to "Hold" at Wall Street Zen

Key Points

• Arcturus Therapeutics has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, while Citigroup reaffirmed its "buy" rating.
• The company reported earnings of ($0.52) EPS for the quarter, surpassing expectations and generating $29.38 million in revenue, higher than the consensus estimate.
• Arcturus Therapeutics has a current market cap of $323 million, with stock trading around $11.91, and institutions hold 94.54% of the company's shares.

Wall Street Zen upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT - Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

Several other analysts have also issued reports on ARCT. Citigroup restated a "buy" rating on shares of Arcturus Therapeutics in a report on Tuesday, May 13th. Canaccord Genuity Group cut their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Finally, Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Arcturus Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $50.00.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock traded up $3.69 during trading on Friday, reaching $18.58. The company had a trading volume of 672,027 shares, compared to its average volume of 448,398. The firm's 50-day simple moving average is $13.15 and its 200 day simple moving average is $13.25. Arcturus Therapeutics has a 1-year low of $8.04 and a 1-year high of $25.88. The firm has a market capitalization of $503.97 million, a PE ratio of -8.39 and a beta of 2.26. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.64 and a current ratio of 5.64.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.11) by $0.77. Arcturus Therapeutics had a negative return on equity of 24.50% and a negative net margin of 49.26%. The company had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Large investors have recently bought and sold shares of the company. ARK Investment Management LLC boosted its stake in Arcturus Therapeutics by 3.9% in the 1st quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company's stock worth $21,270,000 after buying an additional 74,629 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Arcturus Therapeutics by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company's stock worth $18,521,000 after acquiring an additional 64,367 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its position in shares of Arcturus Therapeutics by 129.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock worth $14,409,000 after acquiring an additional 479,482 shares in the last quarter. Woodline Partners LP grew its position in shares of Arcturus Therapeutics by 3.5% in the 4th quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company's stock worth $13,693,000 after acquiring an additional 26,956 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Arcturus Therapeutics by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 606,291 shares of the biotechnology company's stock valued at $7,889,000 after purchasing an additional 36,671 shares during the period. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.